Webinar 1 provides an overview of JAK inhibitors, mechanisms of action, clinical data, and a discussion around current clinical practices.
Webinar 2 provides a roundtable discussion around JAK inhibitor safety data, recommendations, and implications for clinical practice.
This educational activity is free of charge.
Learning Objectives:
The goal of this activity is for learners to be better able to manage patients with IBD (such as Crohn’s disease and ulcerative colitis) through detailed discussions related to JAK inhibitors as a treatment option in light of recent FDA and EMA recommendations.
Upon completion of this activity, learners will be able to:
- Define and explain the terms such as: JAK inhibitors, PRAC (Pharmacovigilance Risk Assessment Committee) procedure, label change.
- Evaluate the clinical evidence of JAK inhibitors in regards to IBD.
- Identify and discuss the U.S. Food and Drug Administration (FDA) and European Medical Agency (EMA) recommendations of JAK inhibitor use in the context of IBD treatment.
- Compare and contrast the recent EMA and FDA recommendations.
- Explain and evaluate the PRAC procedure and decision-making outcomes in regards to clinical practice.
- Recognise and use the recommendations from the PRAC and evaluate how this will impact clinical practice and recognise the most appropriate approach for each patient with clear explained choices.
Faculty
Tim Raine, MD
Consultant Gastroenterologist and IBD lead, Cambridge University Hospitals NHS Foundation Trust, UK
Clinician and Honorary Faculty at the Wellcome Sanger Institute
Rocío Sedano, MD
Research fellow Department of Medicine, Division of Gastroenterology, Western University / Alimentiv Inc., Ontario, Canada
Benjamin L. Cohen, MD
Staff Physician and Co-Section Head and Clinical Director for Inflammatory Bowel Diseases in the Department of Gastroenterology, Hepatology, and Nutrition at the Cleveland Clinic, Cleveland, OH, USA
